• 

  For Patients on Discontinued Aduhelm, What Now?
• 

  No More Aduhelm: Biogen Halts Sales of Alzheimer’s Drug
• 

  Phil’s Journal: What Is ‘Quality of Life?’ A Sad Farewell and a Tough Deciscion
• 

  Medicare Stands Firm: No Public Coverage for New Alzheimer’s Drugs
• 

  Phil’s Journal: Why Voices of Alzheimer’s? Because ‘Silence Equals Death’
• 

  How Much Does Aduhelm Cost?
• 

  Doctors Told Her Her Early-Onset Alzheimer’s Was ‘Just Stress’
• 

  Hyperbole, Misinfo: Alzheimer’s Experts Say Recent Amyloid Fraud Claims Get It All Wrong 
• 

  FDA Fast-Tracks Alzheimer’s Drug Lecanemab; Decision Expected By Early 2023
• 

  More Aduhelm Drama: Packaging Could Waste Medicare Millions; Trial Tossed
• 

  Phil’s Journal: The Face of Alzheimer’s Is Changing — Are We Ready?
• 

  FDA Ups ARIA Monitoring for Aduhelm; Doubles MRI Requirement
• 

  Biogen Abandons Aduhelm Approval Process in Europe 
• 

  CMS Says No Aduhelm Coverage for Patients Outside Clinical Trials
• 

  Op-Ed on Aduhelm and Medicare: “Don’t Limit Our Hope”

12Next